|
1）Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012; 74: 351-75
|
|
|
|
2）Tang SC, Leung JC, Lai KN. Diabetic tubulopathy: an emerging entity. Contrib Nephrol. 2011; 170: 124-34
|
|
|
|
|
|
3）Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013; 19: 1496-504
|
|
|
|
|
|
4）de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol. 2007; 27: 172-81
|
|
|
|
|
|
5）Mauer SM, Steffes MW, Ellis EN, et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984; 74: 1143-55
|
|
|
|
|
|
6）Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007; 27: 195-207
|
|
|
|
|
|
7）Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006; 17: 2974-84
|
|
|
|
|
|
8）Miltényi M, Körner A, Tulassay T, et al. Tubular dysfunction in type I diabetes mellitus. Arch Dis Child. 1985; 60: 929-31
|
|
|
|
|
|
9）Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010; 28: 486-94
|
|
|
|
|
|
10）Hørlyck A, Gundersen HJ, Osterby R. The cortical distribution pattern of diabetic glomerulopathy. Diabetologia. 1986; 29: 146-50
|
|
|
|
|
|
11）Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int. 2011; 79: 464-70
|
|
|
|
|
|
12）Bader R, Bader H, Grund KE, et al. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract. 1980; 167: 204-16
|
|
|
|
|
|
13）Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011; 300: R1009-22
|
|
|
|
|
|
14）Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014; 5: 53-61
|
|
|
|
|
|
15）Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014; 9: e100777
|
|
|
|
|
|
16）Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-97
|
|
|
|
|
|
17）Guarente L, Franklin H. Epstein lecture: Sirtuins, aging, and medicine. N Engl J Med. 2011; 364: 2235-44
|
|
|
|
|
|
18）Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003; 100: 10794-9
|
|
|
|
|
|
19）Hasegawa K, Wakino S, Yoshioka K, et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun. 2008; 372: 51-6
|
|
|
|
|
|
20）Hasegawa K, Wakino S, Yoshioka K, et al. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem. 2010; 285: 13045-56
|
|
|
|
|
|
21）Wang P, Xu TY, Guan YF, et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009; 81: 370-80
|
|
|
|
|
|
22）Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011; 22: 545-53
|
|
|
|
|
|
23）Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, et al. Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol. 2014; 10: 325-46
|
|
|
|
|